Skip to content
National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
Division of Cancer Prevention logo
Home Site Map Contact DCP
Programs & Resources

Prostate and Urologic Cancer Research Group

Publications

View All  |  2014-2010  |  2009-2006

2014

  • Coming soon.

2013

  • Algotar AM, Stratton MS, Ahmann FR, Ranger-Moore J, Nagle RB, Thompson PA, Slate E, Hsu CH, Dalkin BL, Sindhwani P, Holmes MA, Tuckey JA, Graham DL, Parnes HL, Clark LC, Stratton SP. Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer. Prostate. 2013 Feb 15;73(3):328-35.
    [ PubMed Abstract ]
  • Brasky TM, Darke AK, Song X, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL Jr, Goodman GE, Minasian LM, Parnes HL, Klein EA, Kristal AR. Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst. 2013 Aug 7;105(15):1132-41.
    [ PubMed Abstract ]
  • Dahut WL, Madan RA, Karakunnel JJ, Adelberg D, Gulley JL, Turkbey IB, Chau CH, Spencer SD, Mulquin M, Wright J, Parnes HL, Steinberg SM, Choyke PL, Figg WD. Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. BJU Int. 2013 Jun;111(8):1269-80.
    [ PubMed Abstract ]
  • Neuhouser ML, Platz EA, Till C, Tangen CM, Goodman PJ, Kristal A, Parnes HL, Tao Y, Figg WD, Lucia MS, Hoque A, Hsing AW, Thompson IM, Pollak M. Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the prostate cancer prevention trial. Cancer Prev Res (Phila). 2013 Feb;6(2):91-9.
    [ PubMed Abstract ]
  • Parnes HL, House MG, Tangrea JA. Prostate cancer prevention: strategies for agent development. Curr Opin Oncol. 2013 May;25(3):242-51
    [ PubMed Abstract ]
  • Pinsky PF, Parnes HL, Andriole G. Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial. BJU Int. 2013 Jul 19.
    [ PubMed Abstract ]
  • Stamatakis L, Siddiqui MM, Nix JW, Logan J, Rais-Bahrami S, Walton-Diaz A, Hoang AN, Vourganti S, Truong H, Shuch B, Parnes HL, Turkbey B, Choyke PL, Wood BJ, Simon RM, Pinto PA. Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer. Cancer. 2013 Sep 15;119(18):3359-66.
    [ PubMed Abstract ]
  • Thompson IM Jr, Goodman PJ, Tangen CM, Parnes HL, Minasian LM, Godley PA, Lucia MS, Ford LG. Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med. 2013 Aug 15;369(7):603-10.
    [ PubMed Abstract ]

2012

  • Curiel-Lewandowski C, Swetter S, Einspahr JG, Hsu CH, Nagle R, Sagerman P, Tangrea J, Parnes H, Alberts DS, Chow HH. Randomized, double-blind, placebo-controlled trial of sulindac in individuals at risk for melanoma: evaluation of potential chemopreventive activity. Cancer. 2012, in press.
  • Messing E, Gee JR, Saltzstein DR, Kim K, diSant'Agnese A, Kolesar J, Harris L, Faerber A, Havighurst T, Young JM, Efros M, Getzenberg RH, Wheeler MA, Tangrea J, Parnes H, House M, Busby J, Hohl R, Bailey H. A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients. Cancer Prev Res (Phila). 2012 Jan 31. [Epub ahead of print ].
    [ PubMed Abstract ]
  • Nguyen MM, Ahmann FR, Nagle RB, Hsu CH, Tangrea JA, Parnes HL, Sokoloff MH, Gretzer MB, Chow HH. Randomized, double-blind, placebo-controlled trial of Polyphenon E in prostate cancer before prostatectomy: evaluation of potential chemopreventive activities. Cancer Prev Res (Phila). 2012 Feb: 5(2); 290-8.
    [ PubMed Abstract - in process ]

2011

  • Kidd LR, Hein DW, Woodson K, Taylor PR, Albanes D, Virtamo J, Tangrea JA. Lack of association of the N-acetyltransferase NAT1*10 allele with prostate cancer incidence, grade or stage among smokers in Finland. Biochem Genet. 2011 Feb;49(1-2):73-82. Epub 2010 Oct 8.
    [ PubMed Abstract ]
  • Parnes, HL. Prostate Cancer Prevention: Do the 5-ARIs make the grade? Am J Bioeth. 2011 Dec;11(12):30-1.
    [ PubMed Abstract - in process ]
  • Parnes H, House M, Tangrea J. Updates in prostate cancer prevention. Emerging Cancer Therapeutics. 2011, in review.
  • Yao S, Till C, Kristal AR, Goodman PJ, Hsing AW, Tangen CM, Platz EA, Stanczyk FZ, Reichardt JK, Tang L, Neuhouser ML, Santella RM, Figg WD, Price DK, Parnes HL, Lippman SM, Thompson IM, Ambrosone CB, Hoque A.  Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control study. Cancer Causes Control. 2011 Aug;22(8):1121-31.
    [ PubMed Abstract ]

2010

  • Baker SG, Darke AK, Pinsky P, Parnes HL, Kramer BS. Transparency and reproducibility in data analysis: the Prostate Cancer Prevention Trial. Biostatistics. 2010 Jul;11(3):413-8. Epub 2010 Feb 19.
    [ PubMed Abstract ]
  • Brock KE, Graubard BI, Fraser DR, Weinstein SJ, Stolzenberg-Solomon RZ, Lim U, Tangrea JA, Virtamo J, Ke L, Snyder K, Albanes D. Predictors of vitamin D biochemical status in a large sample of middle-aged male smokers in Finland. Eur J Clin Nutr. 2010 Mar; 64(3): 280-8. Epub 2010 Jan 6.
    [ PubMed Abstract ]
  • Figg WS, Woo S, Zhu W, Chen X, Ajiboye AS, Steinberg SM, Price DK, Wright JJ, Parnes HL, Arlen PM, Gulley JL, Dahut WL . A phase I clinical study of high-dose ketoconazole plus weekly docetaxel in metastatic castration-resistant prostate cancer. J Urol. 2010 Jun;183(6):2219-26.
    [ PubMed Abstract ]
  • Gibson TM, Ferrucci LM, Tangrea JA, Schatzkin A. Epidemiological and clinical studies of nutrition. Semin Oncol. 2010 Jun; 37(3):282-96.
    [ PubMed Abstract ]
  • Goodman PJ, Tangen CM, Kristal AR, Thompson IM, Lucia MS, Platz EA, Figg WD, Hoque A, Hsing A, Neuhouser ML, Parnes HL, Reichardt JK, Santella RM, Till C, Lippman SM. Transition of a clinical trial into translational research: the prostate cancer prevention trial experience. Cancer Prev Res (Phila). 2010 Dec;3(12):1523-33.
    [ PubMed Abstract ]
  • Hoque A, Ambrosone CB, Till C, Goodman PJ, Tangen C, Kristal A, Lucia S, Wang Q, Kappil M, Thompson I, Hsing AW, Parnes H, Santella RM. Serum oxidized protein and prostate cancer risk within the Prostate Cancer Prevention Trial. Cancer Prev Res (Phila Pa). 2010 Apr;3(4):478-83. Epub 2010 Mar 23.
    [ PubMed Abstract ]
  • Lerner SP, Grossman HB, Messing EM, Kibel AS, Stephenson A, Gee JR, O'Donnell MA, Reid RD, Kamat AM, Parnes HL, House MG. BCAN Think Tank session 3: prevention of bladder cancer.  Urol Oncol. 2010 May-Jun;28(3):338-42.
    [ PubMed Abstract ]
  • Ning YM, Gulley JL, Arlen PM, Woo S, Steinberg SM, Wright JJ, Parnes HL, Trepel JB, Lee MJ, Kim YS, Sun H, Madan RA, Latham L, Jones E, Chen CC, Figg WD, Dahut WL. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2010 Apr 20;28(12):2070-6. Epub 2010 Mar 22.
    [ PubMed Abstract ]
  • Neuhouser ML, Till C, Kristal A, Goodman P, Hoque A, Platz EA, Hsing AW, Albanes D, Parnes HL, Pollak M.  Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Cancer Prev Res (Phila Pa). 2010 Mar;3(3):279-89. Epub 2010 Feb 23.
    [ PubMed Abstract ]
  • Parnes HL, House MG, Tangrea JA. Prostate cancer chemoprevention strategies, in Drug Management of Prostate Cancer. Figg et al, Editors. Springer-New York, 2010.
  • Price DK, Chau CH, Till C, Goodman PJ, Baum CE, Ockers SB, English BC, Minasian L, Parnes HL, Hsing AW, Reichardt JK, Hoque A, Tangen CM, Kristal AR, Thompson IM, Figg WD. Androgen receptor CAG repeat length and association with prostate cancer risk: results from the Prostate Cancer Prevention Trial.  J Urol. 2010 Dec;184(6):2297-302. Epub 2010 Oct 16.
    [ PubMed Abstract ]

2009

  • Antonarkis ES, Heath EI, Walczak JR, Nelson WG, Fedor H, De Marzo AM, Zahurak ML, Piantadosi S, Dannenberg AJ, Gurganus RT, Baker SD, Parnes, HL, DeWeese TL, Partin AW, Carducci MA.  Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol. 2009 Oct 20;27(30):4986-93. Epub 2009 Aug 31.
    [ PubMed Abstract ]
  • Aragon-Ching JB, Ning YM, Chen CC, Latham L, Guadagnini JP, Gulley JL, Arlen PM, Wright JJ, Parnes H,  Figg WD, Dahut WD. Osteonecrosis of the jaw in patients with metastatic castrate-resistant prostate cancer treated in a phase 2 study of the combination of bevacizumab, docetaxel, thalidomide, and prednisone. Cancer Invest. (Serial.) 2009 27(2):221-6.
  • Figg WD, Hussain MH, Gulley JL, Arlen PM, Aragon-Ching, JB, Petrylak DP, Higano CS, Steinberg SM, Chatta GS, Parnes H, Wright JJ, Sartor O, and Dahut WL. A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. J Urol. 2009 Mar;181(3):1104-13; discussion 1113. Epub 2009 Jan 23.
    [ PubMed Abstract ]
  • Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, Jones JL, Poole DJ, Higgins JP, Hodge JW, Cereda V, Vergati M, Steinberg SM, Halabi S, Jones E, Chen C, Parnes H, Wright JJ, Dahut WL, Schlom J. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.  Cancer Immunol Immunother. 2010 May;59(5):663-74. Epub 2009 Nov 5
    [ PubMed Abstract ]
  • Lippman SM, Klein EA, Goodman PJ, Lucia M S, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD, Crawford ED Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL, Baker LH, Coltman CA.  Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009 Jan 7;301(1):39-51. Epub 2008 Dec 9.
    [ PubMed Abstract ]
  • Platz EA, Till C, Goodman PJ, Parnes HL, Figg WD, Albanes D, Neuhouser ML, Klein EA, Thompson IM Jr, Kristal AR. Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2807-13. Epub 2009 Nov 3.
    [ PubMed Abstract ]
  • Sansbury LB, Wanke K, Albert PS, Kahle L, Schatzkin A, Lanza E; Polyp Prevention Trial Study Group. The effect of strict adherence to a high-fiber, high-fruit and vegetable, and low-fat eating pattern on adenoma recurrence. Am J Epidemiol. 2009 Sep 1;170(5):576-84. Epub 2009 Jul 30.
    [ PubMed Abstract ]

2008

  • Faupel-Badger J, Kidd LR, Albanes D, Virtamo J, Woodson K, Tangrea JA. Association of interleukin-10 polymorphisms with prostate cancer risk and grade of disease. Cancer Causes Control, 2008; 19(2): 119-124.
  • Sabichi AL, Lerner SP, Atkinson EN, Grossman HB, Caraway NP, Dinney CP, Penson DF, Matin S, Kamat A, Pisters LL, Lin DW, Katz RL, Brenner DE, Hemstreet GP 3rd, Wargo M, Bleyer A, Sanders WH, Clifford JL, Parnes HL, Lippman SM. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res. 2008 Jan 1;14(1):224-9.
  • Song Y, Tangen C, Goodman P, Parnes HL, Lucia MS, Thompson IM, Kristal AR. Finasteride, prostate cancer, and weight gain: evidence for genetic or environmental factors that affect cancer outcomes during finasteride treatment. Prostate. 2008 Feb 15;68(3):281-6.
  • Tangrea JA, House MG, Parnes HL. Prostate Cancer Epidemiology and Prevention. In: Prostate Cancer: A Clinical Guide. Prostate Cancer Foundation, New York: Lippincott, 2008.

2007

  • Arlen PM, Skarupa L, Pazdur M, Seetharam M, Tsang KY, Grosenbach DW, Feldman J, Poole DJ, Litzinger M, Steinberg SM, Jones E, Chen C, Marte J, Parnes H, Wright J, Dahut W, Schlom J, Gulley JL. Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol. 2007 Oct;178(4 Pt 1):1515-20.
  • Faupel-Badger J, Diaw L, Albanes D, Virtamo J,Woodson K, Tangrea JA. Lack of association between serum levels of 25-hydroxyvitamin D and subsequent risk of prostate cancer in Finnish men. Cancer Epidemiol Biomarkers Prev, 2007; 16(12): 2784-6.
  • Figg WD, Li H, Sissung T, Retter A, Wu S, Gulley JL, Arlen P, Wright JJ, Parnes H, Fedenko K, Latham L, Steinberg SM, Jones E, Chen C, Dahut W. Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. BJU Int. 2007 May;99(5):1047-55.
  • Hoque A, Parnes HL, Stefanek ME, Heymach JV, Brown PH, Lippman SM. Meeting Report: Fifth Annual AACR Frontiers in Cancer Prevention Research. Cancer Res. 2007 Oct 1;67(19):8989-93.
  • Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, Tangen CM, Parnes HL, Lippman SM, La Rosa FG, Kattan MW, Crawford ED, Ford LG, Coltman CA Jr, Thompson IM. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007 Sep 19;99(18):1375-83.
  • Kelloff GJ, Sullivan DC, Baker H, Clarke LP, Nordstrom R, Tatum JL, Dorfman GS, Jacobs P, Berg CD, Pomper MG, Birrer MJ, Tempero M, Higley HR, Petty BG, Sigman CC, Maley C, Sharma P, Wax A, Ginsberg GG, Dannenberg AJ, Hawk ET, Messing EM, Grossman HB, Harisinghani M, Bigio IJ, Griebel D, Henson DE, Fabian CJ, Ferrara K, Fantini S, Schnall MD, Zujewski JA, Hayes W, Klein EA, DeMarzo A, Ocak I, Ketterling JA, Tempany C, Shtern F, Parnes HL, Gomez J, Srivastava S, Szabo E, Lam S, Seibel EJ, Massion P, McLennan G, Cleary K, Suh R, Burt RW, Pfeiffer RM, Hoffman JM, Roy HK, Wang T, Limburg PJ, El-Deiry WS, Papadimitrakopoulou V, Hittelman WN, MacAulay C, Veltri RW, Solomon D, Jeronimo J, Richards-Kortum R, Johnson KA, Viner JL, Stratton SP, Rajadhyaksha M, Dhawan A; Workshop Program Committee. Workshop on imaging science development for cancer prevention and preemption. Cancer Biomark. 2007;3(1):1-33.
  • Thompson IM, Pauler Ankerst D, Chi C, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA Jr. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. J Clin Oncol. 2007 Jul 20;25(21):3076-81.
  • Thompson IM, Lucia MS, Redman MW, Darke A, La Rosa FG, Parnes HL, Lippman SM, Coltman CA. Finasteride decreases the risk of prostatic intraepithelial neoplasia. J Urol. 2007 Jul;178(1):107-9; discussion 110.
  • Thompson IM, Tangen CM, Goodman PJ, Lucia MS, Parnes HL, Lippman SM, Coltman CA Jr. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. J Urol. 2007 May;177(5):1749-52.

2006

  • Gulley JL, Parnes HL, Wright J, Dahut WL. Early treatment gets the benefit. J Clin Oncol. 2006 Nov 10;24(32):5172-3; author reply 5173.
  • Hanson JA, Gillespie JW, Grover A, Tangrea MA, Chuaqui RF, Emmert-Buck MR, Tangrea JA, Libutti SK, Linehan WM, Woodson KG. Gene promoter methylation in prostate tumor-associated stromal cells. J Natl Cancer Inst, 2006, 98: 255-61.
  • Parnes HL, Figg WD. Chemoprevention in prostate cancer. Pharmacotherapy. 2006 Oct;26(10):1533; author reply 1533.
  • Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA Jr. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst. 2006 Aug 16;98(16):1128-33.
  • Messing E, Kim KM, Sharkey F, Schultz M, Parnes H, Kim D, Saltzstein D, Wilding G. Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer. J Urol. 2006 Aug;176(2):500-4.
  • Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan VC, Spitz MR, Mills GB, Papadimitrakopoulou VA, Lotan R, Aggarwal BB, Bresalier RS, Kim J, Arun B, Lu KH, Thomas ME, Rhodes HE, Brewer MA, Follen M, Shin DM, Parnes HL, Siegfried JM, Evans AA, Blot WJ, Chow WH, Blount PL, Maley CC, Wang KK, Lam S, Lee JJ, Dubinett SM, Engstrom PF, Meyskens FL Jr, O'Shaughnessy J, Hawk ET, Levin B, Nelson WG, Hong WK; AACR Task Force on Cancer Prevention. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res. 2006 Jun 15;12(12):3661-97.
  • Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, Feng Z, Parnes HL, Coltman CA Jr. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.J Natl Cancer Inst. 2006 Apr 19;98(8):529-34.
  • Yang HP, Woodson K, Taylor PR, Pietinen P, Albanes D, Virtamo J, Tangrea JA. Genetic variation in interleukin 8 and its receptor genes and its influence on the risk and prognosis of prostate cancer among Finnish men in a large cancer prevention trial. European J Cancer Prev, 2006, 15: 249-53.

Back to top